Elahere™ (mirvetuximab soravtansine-gynx) – New orphan drug approval
November 14, 2022 - ImmunoGen announced the FDA approval of Elahere (mirvetuximab soravtansine-gynx), for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Top